6
Clinical Trials associated with KN-057在不伴抑制物的血友病A和血友病B患者中,评价KN057注射液预防治疗的有效性和安全性的随机、开放研究
[Translation] A randomized, open-label study to evaluate the efficacy and safety of KN057 injection for prophylactic treatment in patients with hemophilia A and hemophilia B without inhibitors
在不伴抑制物的血友病A(HA)和不伴抑制物的血友病B(HB)患者中,评估KN057预防治疗的有效性。
[Translation] The efficacy of KN057 as a preventive therapy was evaluated in patients with hemophilia A (HA) without inhibitors and hemophilia B (HB) without inhibitors.
在伴抑制物的血友病A和血友病B患者中,评价KN057注射液预防治疗的有效性和安全性的随机、开放研究
[Translation] A randomized, open-label study to evaluate the efficacy and safety of KN057 injection for prophylactic treatment in patients with hemophilia A and hemophilia B with inhibitors
在伴抑制物的血友病A(HAW)和伴抑制物的血友病B(HBW)患者中,评估KN057预防治疗的有效性
[Translation] To evaluate the efficacy of KN057 prophylaxis in patients with hemophilia A with inhibitors (HAW) and hemophilia B with inhibitors (HBW).
A Randomized, Open-label Study to Evaluate the Efficacy and Safety of KN057 Injection Prophylaxis in Patients With Hemophilia A or B With Inhibitors
The purpose of this study is to show that KN057 can prevent bleeds in patients with haemophilia A or B with inhibitors and is safe to use. Successfully screened participants will be randomly assigned to KN057 Prophylaxis (Arm 1) versus No Prophylaxis (Arm 2) at a ratio of 2:1. Participants in KN057 Prophylaxis will receive KN057 prophylaxis for 52 weeks upon enrollment. Participants in No Prophylaxis will first receive on-demand treatment for 26 weeks, then switch to KN057 prophylaxis for 26 weeks.The trial period is 59 weeks, including a 3-week screening period, a 26-week main trial, a 26-week extension period, and a 4-week follow-up period after the last administration.
100 Clinical Results associated with KN-057
100 Translational Medicine associated with KN-057
100 Patents (Medical) associated with KN-057
100 Deals associated with KN-057